On March 16, 2020, the SEC filed a complaint in the U.S. District Court for the Southern District of New York against AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), alleging that it violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  The complaint alleges that AcelRx and Tetraphase Pharmaceuticals violated the antifraud provisions of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder and Section 10(b) of the Exchange Act.  The complaint further alleges that AcelRx failed to comply with the Exchange Act and Rule 10b-5.  The SEC's complaint, filed in federal court in New York, charges AcelRx and Tetraphase with violations of Section 10(b) of the Exchange Rules and Rule 10b-5.  The complaint seeks permanent injunctions, disgorgement of ill-gotten gains with prejudgment interest, and civil penalties.  The SEC's complaint charges AcelRx with violating Section 10(b) of the Exchange Act, Section 13(b)(5) of the Exchange Act, and Rule 10b-5 thereunder, and Section 17(a) of the Securities Act.  The complaint also charges AcelRx with violating Rule 10b-5.  The complaint charges AcelRx with violating Section 15(a) of the Exchange Act and Rules 10b-5(a) and (c) thereunder.  Without admitting or denying the SEC's allegations, AcelRx and Tetraphase consented to the entry of a final judgment that permanently enjoins them from violating the Exchange Act and Rules 10b-5, 13a-1, 13a-11, and 13a-13 thereunder.  The settlement is subject to court approval.  The SEC's investigation is continuing.  The SEC's litigation is being led by Raffi Asadorian.  The SEC appreciates the assistance of the U.S. Attorney's Office for the Southern District of New York, the Federal Bureau of Investigation, and the Alabama Department of Health and Human Services.